$INSM Q1 Brinsupri sales $208 million, above sell-side consensus but below the buyside "whisper" expectation that has moved around from the $2-teens to $220-ish.
$INSM Insmed drug Arikayce benefits patients with rare, bacterial lung disease, study shows https://t.co/z7FPoZHxoP
$INSM guides to 2026 Brinsupri sales of "at least $1B" in line with consensus. https://t.co/o7JhPKU3m1
Insmed $INSM basks in the success of its lung disease drug — and prepares for what’s next. I chatted Sunday with CEO Will Lewis before watching the Patriots beat the Chargers. #JPM26 https://t.co/l56Y7Xw5fS
$INSM pre-announces Q4 Brinspuri sales of $144.6M. Consensus $67M, per Visible Alpha. Total '25 revenue $606.4 vs consensus $523M 2026 Arikayce revenue forecast $450-470M vs consensus $488M https://t.co/LhY6SRoTY3
@WassimLaroussi3 @aggregategains Apologies for all these questions, but I’m curious if you also were turned off by my bullish $INSM stories and X posts? I don’t follow you here, so excuse for me not noticing, but did you criticize me for saying Insmed could be the next $100 billion biotech? Maybe you didn’t notice, either. That’s ok.
$INSM stumble Phase 2b BiRCh Study of Brensocatib in CRSsNP Did Not Meet Primary or Secondary Efficacy Endpoints; Safety Consistent with Previous Studies; Insmed Discontinues CRSsNP Program— https://t.co/D650qIIxlY
If everyone else can congratulate themselves here, I'm doing it too, dammit. $INSM https://t.co/j3v4Bg6dtC
$INSM with a blowout quarter. Fantastic.
@Biohazard3737 I put together a Q4 list, fairly active heading into end of year, which is nice. Will post it later in the week. $INSM $NKTR $GPCR $CYTK among others
